PMC10160470_01
Clinical course of case 1. AI, albumin infusion; ALT, alanine transaminase; AST, aspartate aminotransferase; CRP, C-reactive protein; CTRX, ceftriaxone; DA, dopamine; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FUR, furosemide; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MEPM, meropenem; MPDN, methylprednisolone; PCT, procalcitonin; pro-BNP, pro-brain natriuretic peptide; PSL, prednisolone; TG, triglycerides; VA, vancomycin; WBC, white blood cell.
fped-11-1152242-g001.jpg
PMC10160470_01_fped-11-1152242-g001.jpg
F1
Low-dose dopamine was administered along with intravenous pulse methylprednisolone (MPDN; 25 mg/kg/day for three days), significantly improving clinical and biochemical abnormalities (Figure 1).
PMC10160470_02
Clinical course of case 2. AI, albumin infusion; ALT, alanine transaminase; AST, aspartate aminotransferase; CRP, C-reactive protein; CRRT, continuous renal replacement therapy; DA, dopamine; DBTM, dobutamine; DX, digoxin; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MEPM, meropenem; MN, milrinone; MPDN, methylprednisolone; MV, mechanical ventilation; NE, norepinephrine; PCT, procalcitonin; PIT, piperacillin-tazobactam; pro-BNP, pro-brain natriuretic peptide; TG, triglycerides; VA, vancomycin; WBC, white blood cell.
fped-11-1152242-g002.jpg
PMC10160470_02_fped-11-1152242-g002.jpg
F2
After the patient was administered pulse intravenous MPDN (15 mg/kg/day for three days), low-dose maintenance therapy, vasoactive drugs, invasive mechanical ventilation, cardiac and diuretic treatment, continuous renal replacement therapy (CRRT), fluid resuscitation, antibiotic escalation to vancomycin and meropenem, correction of electrolyte disturbances, repeated intravenous human albumin infusion, and blood transfusion, the symptoms and laboratory test results gradually improved (Figure 2).